有趣的是，Infigratinib最初于2021年获批用于胆管癌，后因适应症开发策略调整而主动撤回。如今，其有望在ACH赛道迎来“第二春”。基于其疗效和口服便利性，BridgeBio在今年的JPM大会上预测，该药Infigratinib将占据ACH治疗市场50%以上的份额。
© 2014-2026 上海东方报业有限公司，更多细节参见WPS下载最新地址
Nasa was targeting March for the launch, but its plans were delayed after a helium leak was discovered on the Space Launch System (SLS) rocket.，详情可参考WPS下载最新地址
Fast speech recognition with NVIDIA's Parakeet models in pure C++.